Sernova Corp. (SEOVF)
Sernova Corp.
The Stiller Centre
Suite 114 700 Collip Circle
London, ON N6G 4X8
Canada
519 858 5126
https://www.sernova.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Cynthia Pussinen | CEO & Director | 401.78k | N/D | N/D |
| Dr. Modestus Obochi M.B.A., Ph.D. | Chief Business Officer | 220.05k | N/D | N/D |
| Dr. Frank Shannon M.D. | Vice President of Clinical Development & Regulatory Affairs | 254.34k | N/D | N/D |
| Mr. Nicholas J. Rossettos CPA, M.B.A. | Interim Chief Financial Officer | N/D | N/D | 1966 |
| Mr. Douglas Maret | Chief Science Officer | N/D | N/D | N/D |
| Mr. Christopher Barnes | Vice President of Investor Relations | 119.27k | N/D | N/D |
Descripción
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Sernova Corp. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
